BioSpace News Archive

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share.

Laboratory proficiency testing is the verification of performance of a laboratory for specific tests.

The Contrast Media Agents market was valued at US$ 2,099.9t million in 2018 and it is projected to reach US$ 2,886.3 million by 2027; it is expected to grow at a CAGR of 3.7% from 2029 to 2027.

LeMaitre Vascular, Inc., a provider of peripheral vascular devices, implants and services, announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $54.50 per share.

Allena Pharmaceuticals, Inc. announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company’s common stock and warrants to purchase up to an aggregate of 10,678,872 shares of the Company’s common stock, at a purchase price of $1.311 per share of common stock and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.

Intraoperative Radiation Therapy (IORT) permits the delivery of a single dose of radiation in the course of surgical operations.

To determine genomic elements role in the cellular dysfunction and function and to study the gene expression patterns RNA detection is done.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor,

The pain management devices market is expected to reach US$ 8,388.67 million in 2027 from US$ 4,527.31 million in 2019. The market is estimated to grow with a CAGR of 8.1% from 2020 to 2027.

Inozyme Pharma, Inc. today announced that Gayle Gironda has been appointed as senior vice president of human resources.